Chemours Company (The) (NYSE:CC) – Research analysts at Jefferies Group reduced their Q3 2017 earnings per share estimates for shares of Chemours Company (The) in a report issued on Wednesday. Jefferies Group analyst L. Alexander now forecasts that the specialty chemicals company will earn $0.97 per share for the quarter, down from their prior forecast of $1.03. Jefferies Group currently has a “Buy” rating and a $60.00 target price on the stock. Jefferies Group also issued estimates for Chemours Company (The)’s Q4 2017 earnings at $0.96 EPS, FY2017 earnings at $3.55 EPS and FY2020 earnings at $5.20 EPS.

Other equities research analysts also recently issued research reports about the company. UBS AG reaffirmed a “sell” rating and set a $36.00 price target (up previously from $35.00) on shares of Chemours Company (The) in a report on Wednesday, June 14th. Susquehanna Bancshares Inc raised their price target on Chemours Company (The) from $45.00 to $55.00 and gave the company a “positive” rating in a report on Monday, May 15th. Zacks Investment Research downgraded Chemours Company (The) from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. J P Morgan Chase & Co raised their price target on Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a report on Friday, August 4th. Finally, BidaskClub raised Chemours Company (The) from a “hold” rating to a “buy” rating in a report on Wednesday, July 12th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Chemours Company (The) presently has a consensus rating of “Buy” and an average target price of $46.25.

COPYRIGHT VIOLATION NOTICE: This story was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/09/q3-2017-eps-estimates-for-chemours-company-the-decreased-by-jefferies-group-nysecc.html.

Chemours Company (NYSE:CC) opened at 47.20 on Monday. Chemours Company has a 12 month low of $9.12 and a 12 month high of $50.04. The company has a market cap of $8.73 billion, a price-to-earnings ratio of 30.87 and a beta of 3.63. The company’s 50-day moving average is $42.16 and its 200-day moving average is $37.26.

Chemours Company (The) (NYSE:CC) last announced its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the firm posted $0.27 earnings per share. Chemours Company (The)’s revenue was up 14.8% compared to the same quarter last year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Thursday, August 17th will be given a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a yield of 0.25%. The ex-dividend date of this dividend is Tuesday, August 15th. Chemours Company (The)’s payout ratio is 8.11%.

In other Chemours Company (The) news, insider Paul Kirsch sold 19,036 shares of the stock in a transaction on Monday, June 5th. The stock was sold at an average price of $41.42, for a total transaction of $788,471.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Erich Parker sold 4,908 shares of the stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total value of $223,461.24. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of CC. Cypress Capital Management LLC WY boosted its position in Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock valued at $162,000 after buying an additional 80 shares during the last quarter. Charter Trust Co. boosted its position in Chemours Company (The) by 2.1% in the second quarter. Charter Trust Co. now owns 5,720 shares of the specialty chemicals company’s stock valued at $217,000 after buying an additional 120 shares during the last quarter. Advisor Partners LLC boosted its position in Chemours Company (The) by 1.4% in the first quarter. Advisor Partners LLC now owns 9,821 shares of the specialty chemicals company’s stock valued at $378,000 after buying an additional 140 shares during the last quarter. Neuberger Berman Group LLC boosted its position in Chemours Company (The) by 1.5% in the first quarter. Neuberger Berman Group LLC now owns 9,579 shares of the specialty chemicals company’s stock valued at $369,000 after buying an additional 141 shares during the last quarter. Finally, Commerce Bank boosted its position in Chemours Company (The) by 3.0% in the second quarter. Commerce Bank now owns 7,158 shares of the specialty chemicals company’s stock valued at $272,000 after buying an additional 206 shares during the last quarter. Hedge funds and other institutional investors own 75.21% of the company’s stock.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Earnings History and Estimates for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.